Trial Profile
A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs LHC-165 (Primary) ; Spartalizumab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 07 Dec 2022 Trial has been completed for Japan,Asia(other than Japan), North America,Europe locations, according to Japic registry
- 28 Jul 2022 Status changed from active, no longer recruiting to discontinued.
- 22 Jun 2022 Planned End Date changed from 5 Aug 2022 to 11 Jul 2022.